Identifying Electrocardiographic Markers to Determine Eligibility for the Implantation of a Subcutaneous Defibrillator.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2027-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The S-ICD defibrillator developed by Boston Scientific Inc. is a fully subcutaneous automatic defibrillation system that prevents and treats sudden cardiac arrest. The subcutaneous system offers the advantage of avoiding the risks associated with transvenous access, limiting serious infections and lead failures. The detection system is based on the identification of rapid ventricular arrhythmias using one of three bipolar vectors defined by the subcutaneous lead (distal and median electrode) and the generator. However, before implanting the device in a patient, it is essential to carry out a screening procedure to ensure that the patient's QRS signal amplitude is sufficient to be detected by the S-ICD. This screening procedure is carried out by recording a specific three-lead electrocardiogram (ECG), which represents the three bipolar vectors of the S-ICD. The aim of this research is to show that the recording of a standard 12-lead ECG can be sufficient to predict the eligibility of patients for S-ICD implantation. More specifically, it aims to identify electrocardiographic markers on a standard 12D-ECG that can be used to determine which patients may benefit from implantation of a subcutaneous defibrillator, thereby eliminating the need for a 3-lead screening ECG. The developments that will be carried out will be based on the development of signal analysis algorithms and decision support using artificial intelligence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation

NCT01117792

ACC/AHA/NASPE Class 1, IIa or IIb Indications

COMPLETED NA

ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients

NCT00399412

Long QT Syndrome Wide QRS Complexes Heart Failure +1 more

COMPLETED

Further Acute Research of a Subcutaneous Implantable Defibrillator (S-ICD) System

NCT00399217

Ventricular Fibrillation Ventricular Tachycardia

COMPLETED

Initial Chronic Human Validation Study: Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System

NCT00853645

Ventricular Tachyarrhythmias

COMPLETED NA

S-ICD® System Post Approval Study

NCT01736618

Primary Prevention of Sudden Cardiac Arrest Secondary Prevention of Sudden Cardiac Arrest

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who meet the study's eligibility criteria will receive an information note describing the study by email or post one to two weeks before their cardiology consultation. Patients will be offered inclusion in the study by their cardiologist during a follow-up cardiology consultation as part of their routine care. During this visit, and for patients meeting the eligibility criteria, oral consent will be obtained. The patient will then be included in the study.

Two arms will be set up depending on the screening result: a group with patients who screened negative and a group with patients who screened positive.

No follow-up is planned as part of the study. Clinical data will be collected in a parameterised and secure eCRF. Data analysis: the 12-lead ECG scans will be analysed using deep learning methods (convolutional neural network), which will be prototyped and trained to predict the outcome of the S-ICD screening with a high accuracy score.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Defibrillator ECG

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Identifying electrocardiographic markers on a 12-lead ECG

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient undergoing cardiology consultation, whatever the pathology
* Patient over 18 years of age
* Patient having been informed and having given their oral non-opposition
* Patient and relatives affiliated to a social security scheme

Exclusion Criteria

* Patients receiving cardiac stimulation
* Patient taking part in a therapeutic trial which may interfere with the results of the research
* Patients under guardianship.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No